Yuwell Medical has announced a strategic investment in Inogen, a US-based respiratory health company. Through its Hong Kong subsidiary, Yuwell will invest approximately $27.2 million for a 9.9% stake in Inogen's common stock. The partnership will focus on four key areas: international distribution, trademark licensing, joint research and development, and supply chain optimisation. Both companies specialise in oxygen concentrators and aim to combine their expertise across different markets. At Yuwell's 2025 Global Core Partner Conference, Chairman Alex Wu outlined the company's five-year vision to become one of the top three global players in home medical health. Yuwell identified respiratory treatment solutions, diabetes care, and emergency services as its three strategic priorities for international expansion.

Inogen, a medical technology company specialising in respiratory products, has appointed Andy Reding as Chief Operating Officer, effective 6 July 2026. Reding will oversee revenue and operational performance whilst aligning cross-functional priorities as the company pursues new product launches and geographic expansion. Reding brings over 30 years of experience in medical technology. Most recently, he served as Chief Commercial Officer at Viant Medical for six years, where he led teams across 25 facilities. He previously held leadership roles at Hillrom Respiratory Health, managing sales, marketing and product development. As part of his employment, Reding will receive 130,000 restricted stock units vesting over three years. He holds an MBA from the University of South Carolina and a bachelor's degree from Marquette University.

Inogen, a medical technology company offering respiratory products, reported first-quarter 2026 revenue of $85.1 million, up 3.4% year-over-year, exceeding guidance. The company reiterated its full-year 2026 revenue outlook of $366 million to $373 million. The Beverly, Massachusetts-based firm posted a GAAP net loss of $8.3 million, compared to a $6.2 million loss in the prior-year period. Adjusted EBITDA was negative $1.4 million, down from positive $0.04 million a year earlier, due to increased research and development investments. Inogen authorised a $30 million share repurchase programme and appointed Jason Richardson as chief financial officer. The company also launched Aurora CPAP masks in the US, entering the obstructive sleep apnea market, and introduced its Rove 6 portable oxygen concentrator in Brazil.